Physician profile
Trinity Bivalacqua
NPI 1265579254
$100,119.93
in general payments reported to CMS, 2019-2025
18 companies · $8,695 in 2025
The $8,695 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $9,613 · 2021: $19K · 2022: $5,043 · 2023: $22K · 2024: $7,879 · 2025: $8,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Honoraria: $9,555 · Travel and Lodging: $2,140 · Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,250.00 |
| Honoraria | $9,555.00 |
| Travel and Lodging | $2,140.31 |
| Food and Beverage | $1,287.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $26,627.88 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $18,844.95 | 2019-2023 | |
| Photocure INC | $17,426.68 | 2019-2022 | |
| Ferring Pharmaceuticals As | $15,650.00 | 2023 | Adstiladrin |
| Pfizer INC. | $6,401.50 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $4,600.00 | 2020-2022 | |
| Janssen Global Services, LLC | $3,746.44 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $3,450.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,192.00 | 2022 | |
| Merck Sharp & Dohme LLC | $1,000.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $505.00 | 2021 | |
| Coloplast Corp | $299.65 | 2022 | |
| Seagen INC. | $162.96 | 2021 | |
| Janssen Biotech, INC. | $116.64 | 2025 | Rybrevant, Carvykti |
| Baxter Healthcare | $58.65 | 2025 | Tisseel, Floseal |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.58 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinity Bivalacqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.